Patients with T2D and CKD have a very high risk of CV events. Listen as Dr. Jorge Plutzky and Dr. Neha Pagidipati discuss new therapies to manage cardiovascular and renal risk in patients with T2D. Their discussion is based on new science presented during AHA Scientific Sessions 2020.
Creators & Guests
We don't know anything about the creators of this episode yet. You can add them yourself so they can be credited for this and other podcasts.
This episode hasn't been reviewed yet. You can add a review to show others what you thought.
This podcast, its content, and its artwork are not owned by, affiliated with, or endorsed by Podchaser.